آنتی‌ بادی S100-P Protein (16/F5)

Name: Antibody Protein S100 clone 16/F5

Composition: Anti-human S100-P Protein mouse monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide

Description and applications: The S100P protein, or placental S100, which is a member of the large S100 protein family, is involved in Ca2+ intracellular transport and, together with EZR and PPP5C proteins, participates in the formation of microvilli in epithelial cells and stimulates apocrine cell secretion. Unlike the genes of the other members of the S100 family of proteins, which co-localise in the 1q21 region, the S100P protein is encoded by the S100P gene, located in the 4p16 region. The 100 family of proteins is expressed in a wide range of cells, where it plays a role in cell cycle progression and in cell differentiation. The S100P molecule was initially identified in the human placenta at rather high levels. Pathologically, the antibody against the S100P protein has shown nuclear or nuclear/cytoplasmic immunoreactivity in almost all pancreatic ductal adenocarcinomas, while it displays no staining in normal ducts and in pancreatic acini. In addition, the S100P protein has also been detected in virtually all pancreatic intraductal papillary mucinous neoplasms, as well as in its microinvasive and diffusely invasive component, including tumours with perineural and lymphatic invasion. For both reasons, the antibody against the S100P protein is considered a useful tool for the differential diagnosis between reactive and neoplastic lesions of the pancreas. In the case of liver and bile ducts, the antibody also exhibits marked nuclear and cytoplasmic positivity in malignant lesions derived from bile ducts, while the benign epithelium derived from these tumours is negative. Similarly, detection of both S100P and GATA3 may help to distinguish urothelial carcinomas from other genitourinary neoplasms such as prostate cancers and renal cell carcinomas; in this case, however, and in contrast to what is observed in biliary and pancreatic ductal lesions, S100P expression can be detected in the normal urothelium. Finally, the anti-S100P antibody can be used as a prognostic factor in non-small cell lung carcinomas, where S100P expression has been associated with frequent distant metastases and short survival.